We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Gets Untitled Letter, Reveals R&D Strategy to Avoid Another Patent Cliff
Sanofi Gets Untitled Letter, Reveals R&D Strategy to Avoid Another Patent Cliff
September 7, 2011
CBER has handed Sanofi an untitled letter over its Fluzone flu vaccine promotions following seven advisory letters to the company on Fluzone promotions.